

Specialty Quantity Limit

Orzeyful

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Orzeyful	oveporexton

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Orzeyful (oveporexton) 0.5 mg tablet	60 per 30 days
Orzeyful (oveporexton) 1 mg tablet	60 per 30 days
Orzeyful (oveporexton) 2 mg tablet	60 per 30 days

FDA-recommended Dosing

Either 1 mg after awakening and then 1 mg three to five hours later or 2 mg after awakening and then 2 mg three to five hours later.

The maximum recommended total dosage is 4 mg per day.

Reference number(s)
7475-H

If Orzeyful is used concomitantly with moderate CYP3A inhibitors, reduce the dosage to 0.5 mg orally after awakening and then 0.5 mg three to five hours later (maximum recommended total dosage is 1 mg per day).

References

1. Orzeyful [package insert]. Cambridge, MA: Takeda Pharmaceuticals America, Inc.; August 2026.